Insect Cell / Baculovirus Protein Expression Service — Publication-Cited BEVS Platform

Service Overview — AtaGenix’s baculovirus–insect cell expression system (BEVS) delivers properly folded, post-translationally modified recombinant proteins for research and preclinical applications. Built on optimized Bac-to-Bac technology with Sf9, Sf21, and Hi5 host lines, the platform supports milligram-to-gram scale production with short turnaround, high throughput, and full-process QC — backed by 15 years of project delivery experience (ISO 9001 & ISO 13485 certified).

Background: This study clarified how DNA polymerase POLD1 drives bladder cancer proliferation and metastasis through a positive feedback loop with MYC, revealing a new diagnostic and therapeutic target.

AtaGenix’s Role: Produced high-activity GST-MYC recombinant protein via BEVS. Used as the core reagent in GST pull-down assays, it directly validated the specific binding of POLD1 to the MYC homology box 1 domain, confirming that POLD1 stabilizes MYC by competitively binding FBXW7.

Published in Nature Communications (IF: 14.7) — DOI: 10.1038/s41467-023-38160-x

Fig. 1. POLD1 is a direct binding partner of MYC. GST pull-down assay using AtaGenix-produced GST-MYC protein. Adapted from Wen et al., Nat Commun 2023.

Background: Targeting high PADI4 expression in breast cancer, this study developed monoclonal antibodies to inhibit fibronectin citrullination and improve the tumor microenvironment.

AtaGenix’s Role: Constructed and screened high-specificity anti-human PADI4 monoclonal antibodies via hybridoma technology. The antibodies inhibited fibronectin citrullination, reduced EMT-related gene expression, and significantly suppressed breast cancer cell proliferation and migration in both in vitro and in vivo models.

Published in Biomedicine & Pharmacotherapy (IF: 6.9) — DOI: 10.1016/j.biopha.2022.113289

Fig. 2. Identification of citrullination of fibronectin using AtaGenix-produced anti-PADI4 mAb. Adapted from Zhu et al., Biomed Pharmacother 2022.

Background: This study investigated the SERBP1-PCIF1 complex in m⁶Am modification and its regulatory role in neuropathic pain with comorbid anxiety, identifying new therapeutic targets.

AtaGenix’s Role: Expressed and purified the recombinant PCIF1-MTase domain protein in vitro. The high-purity protein was used in methyltransferase activity assays, validating the synergistic catalytic effect of SERBP1-PCIF1 interaction on m⁶Am modification and providing key evidence for the “SERBP1-PCIF1-Maf1” regulatory axis.

Published in Nature Communications (IF: 14.7) — DOI: 10.1038/s41467-025-62565-5

Fig. 3. SERBP1 and PCIF1 interact and co-catalyze m⁶Am modifications on mRNA. Adapted from Nat Commun 2025.

Background: This study targeted the glycolytic enzyme ENO1 in cervical cancer, developing monoclonal antibodies to block ENO1-mediated plasminogen activation and inhibit tumor invasion.

AtaGenix’s Role: Expressed and purified ENO1 protein using the Sf9 insect cell baculovirus system for mouse immunization, then constructed and screened five high-activity hybridoma cell lines. The resulting ENO1 mAbs blocked plasminogen activation, inhibiting cervical cancer cell migration and colony formation — establishing the foundation for nanocarrier-mediated targeted therapy.

Published in American Journal of Cancer Research — Source: ajcr.us/article/view/129535

Fig. 4. ENO1 mAbs inhibit invasion and migration of cervical cancer cells. Sf9/BEVS-expressed ENO1 protein was used for immunization and hybridoma screening. Adapted from Am J Cancer Res.

Whether you need recombinant protein production, monoclonal antibody development, or protein interaction validation via BEVS — AtaGenix delivers end-to-end support from gene to purified protein.

Response within 24 hours